NeurAxis, Inc. (NRXS) Deep Dive Video

Summary

A first-to-market, guideline-backed neuromodulation therapy hits a 2026 reimbursement inflection—if NRXS outruns dilution, the upside can be dramatic.

View NRXS stock page · Read the NRXS research report

Loading the video player…